C G Kleer

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1
    M E Gonzalez
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Oncogene 28:843-53. 2009
  2. pmc On how CCN6 suppresses breast cancer growth and invasion
    Wei Huang
    Department of Pathology and 4217 Comprehensive Cancer Center, University of Michigan Medical School, 1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA
    J Cell Commun Signal 6:5-10. 2012
  3. pmc Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells
    Yanhong Zhang
    Department of Pathology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast Cancer Res 7:R1080-9. 2005
  4. pmc E-cadherin expression in primary carcinomas of the breast and its distant metastases
    Paul J Kowalski
    Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Breast Cancer Res 5:R217-22. 2003
  5. ncbi request reprint RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast
    Celina G Kleer
    Department of Pathology and Internal Medicine, University of Michigan, Ann Arbour, MI 48109 0054, USA
    Breast Cancer Res Treat 93:101-10. 2005
  6. ncbi request reprint Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
    Arch Pathol Lab Med 133:1822-5. 2009
  7. pmc EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
    Celina G Kleer
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:11606-11. 2003
  8. ncbi request reprint Fine-needle aspiration of breast carcinomas with prominent lymphocytic infiltrate
    C G Kleer
    Department of Pathology, University of Michigan Medical Center, Ann Arbor 48109 0054, USA
    Diagn Cytopathol 23:39-42. 2000
  9. ncbi request reprint CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Mich 48109, USA
    Cells Tissues Organs 185:95-9. 2007
  10. ncbi request reprint Persistent E-cadherin expression in inflammatory breast cancer
    C G Kleer
    Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    Mod Pathol 14:458-64. 2001

Research Grants

  1. Role of LIBC in Inflammatory Breast Cancer Phenotype
    Celina Kleer; Fiscal Year: 2007
  2. Role of EZH2 in Breast Cancer
    Celina Kleer; Fiscal Year: 2006
  3. Role of EZH2 in Breast Cancer
    Celina Kleer; Fiscal Year: 2009
  4. Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
    Celina Kleer; Fiscal Year: 2009
  5. Role of EZH2 in Breast Cancer
    Celina Kleer; Fiscal Year: 2007
  6. Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
    Celina G Kleer; Fiscal Year: 2010
  7. Role of EZH2 in Breast Cancer Progression
    Celina G Kleer; Fiscal Year: 2010

Detail Information

Publications69

  1. pmc Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1
    M E Gonzalez
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Oncogene 28:843-53. 2009
    ..Blockade of EZH2 may provide a prime target to prevent and/or halt ER-negative breast cancer progression...
  2. pmc On how CCN6 suppresses breast cancer growth and invasion
    Wei Huang
    Department of Pathology and 4217 Comprehensive Cancer Center, University of Michigan Medical School, 1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA
    J Cell Commun Signal 6:5-10. 2012
    ..Thus, our work provides new insights into the functions and mechanisms of tumor suppression exerted by CCN6 in the breast...
  3. pmc Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells
    Yanhong Zhang
    Department of Pathology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast Cancer Res 7:R1080-9. 2005
    ..We hypothesized that inhibition of CCN6 might result in the loss of a growth regulatory function that protects mammary epithelial cells from the tumorigenic effects of growth factors, particularly IGF-1...
  4. pmc E-cadherin expression in primary carcinomas of the breast and its distant metastases
    Paul J Kowalski
    Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Breast Cancer Res 5:R217-22. 2003
    ..We investigate the relationship between E-cadherin expression in primary breast carcinoma and their distant, non-nodal metastases...
  5. ncbi request reprint RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast
    Celina G Kleer
    Department of Pathology and Internal Medicine, University of Michigan, Ann Arbour, MI 48109 0054, USA
    Breast Cancer Res Treat 93:101-10. 2005
    ..We hypothesized that RhoC expression would identify aggressive, non-IBC tumors breast cancer patients at any stage with worse outcomes defined as recurrence and/or metastasis...
  6. ncbi request reprint Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
    Arch Pathol Lab Med 133:1822-5. 2009
    ..These concepts illustrate the important relationships among histopathologic features; genomic profile; single gene abnormalities, such as BRCA1 and EZH2; and growth regulation in this subset of breast carcinomas...
  7. pmc EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
    Celina G Kleer
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:11606-11. 2003
    ..This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation...
  8. ncbi request reprint Fine-needle aspiration of breast carcinomas with prominent lymphocytic infiltrate
    C G Kleer
    Department of Pathology, University of Michigan Medical Center, Ann Arbor 48109 0054, USA
    Diagn Cytopathol 23:39-42. 2000
    ..Lymphocytosis may be part of the carcinoma or may originate from a lymph node involved by metastases. In rare cases, a prominent neutrophilic infiltrate may also be present...
  9. ncbi request reprint CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Mich 48109, USA
    Cells Tissues Organs 185:95-9. 2007
    ..This review will focus on the current knowledge regarding the function of CCN6 in breast cancer with special emphasis on the emerging role of CCN6 as a regulator of the epithelial phenotype and E-cadherin expression in the breast...
  10. ncbi request reprint Persistent E-cadherin expression in inflammatory breast cancer
    C G Kleer
    Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    Mod Pathol 14:458-64. 2001
    ..In our study, we demonstrate that circulating IBC tumor cells strongly express E-cadherin, thereby providing an important exception to the positive association between E-cadherin loss and poor prognosis in breast cancer...
  11. ncbi request reprint Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
    Mod Pathol 15:759-64. 2002
    ..This is the first study suggesting a role for EBV in the pathogenesis of fibroadenomas...
  12. ncbi request reprint WISP3 is a novel tumor suppressor gene of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Oncogene 21:3172-80. 2002
    ..Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis...
  13. pmc Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, 2G332 University Hospital, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Am J Pathol 160:579-84. 2002
    ..RhoC is specifically expressed in invasive breast carcinomas capable of metastasizing, and it may be clinically useful in patients with tumors smaller than 1 cm to guide treatment...
  14. ncbi request reprint Squamous cell carcinoma of the thyroid: an aggressive tumor associated with tall cell variant of papillary thyroid carcinoma
    C G Kleer
    Department of Pathology, University of Michigan Medical Center, Ann Arbor, USA
    Mod Pathol 13:742-6. 2000
    ..Primary SCT is an aggressive neoplasm that may be found in association with TCV. p53 expression and high MIB1 labeling index occur in these tumors and may be useful prognosticators...
  15. ncbi request reprint Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast
    C G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109 0054, USA
    Mod Pathol 14:185-90. 2001
    ..Neither Ki-67 nor p53 can reliably predict recurrence. Histologically high-grade malignant PT have a favorable prognosis if widely excised. We emphasize the importance of adequate margins in the treatment of benign and malignant PT...
  16. pmc Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1
    Wei Huang
    Department of Pathology, University of Michigan Medical School, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0605, USA
    Am J Pathol 172:893-904. 2008
    ..Together, our results lead to a new hypothesis that Snail and ZEB1 are downstream of CCN6 and play a critical role in CCN6-mediated regulation of E-cadherin in breast cancer...
  17. ncbi request reprint Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence
    Kandice E Kilbride
    Department of Surgical Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Ann Surg Oncol 15:3252-8. 2008
    ..The value of axillary staging prior to delivery of neoadjuvant chemotherapy (NEO) for breast cancer is controversial. Our goal was to analyze the prognostic and therapeutic impact of axillary staging on recurrence...
  18. ncbi request reprint Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast
    Lei Ding
    Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Res 66:9352-5. 2006
    ....
  19. ncbi request reprint Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression
    Lisa M Privette
    Department of Human Genetics, University of Michigan, Ann Arbor, Michigan 48109 0638, USA
    Cancer Res 67:6064-74. 2007
    ....
  20. pmc Repression of E-cadherin by the polycomb group protein EZH2 in cancer
    Q Cao
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    Oncogene 27:7274-84. 2008
    ..Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression...
  21. ncbi request reprint Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis
    Rohit Mehra
    Department of Pathology, University of Michigan Medical School, Ann Arbor, 48109, USA
    Cancer Res 65:11259-64. 2005
    ..Our data suggest that immunohistochemical analysis of GATA3 may be the basis for a new clinically applicable test to predict tumor recurrence early in the progression of breast cancer...
  22. doi request reprint Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions
    Lakshmi P Kunju
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Pathol Int 58:620-5. 2008
    ..Despite matching for tumor size, grade 1 IDC have a higher incidence of lymph node metastasis and may have Her-2-neu overexpression compared to TC...
  23. ncbi request reprint RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, 48109, USA
    Clin Cancer Res 12:4485-90. 2006
    ..This study evaluated the expression of RhoC in head and neck carcinoma and investigated the prognostic use of this marker on a large cohort of previously untreated patients with SCCHN...
  24. pmc WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48108, USA
    Neoplasia 6:179-85. 2004
    ....
  25. pmc The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells
    Michael Zeidler
    Department of Pathology, University of Michigan, Arbor, MI, USA
    Neoplasia 7:1011-9. 2005
    ..Our study paves the way for exploring the blockade of EZH2 overexpression as a novel approach for the prevention and treatment of breast cancer...
  26. pmc WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, University of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
    ..We have demonstrated that WISP3 has tumor growth and angiogenesis inhibitory functions in IBC. We hypothesized that RhoC and WISP3 cooperate in the development of IBC...
  27. ncbi request reprint p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma
    Meryem M Koker
    Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI 48109 0054, USA
    Am J Surg Pathol 28:1506-12. 2004
    ..7% and 99.4%, respectively. We propose the inclusion of p63 as part of the diagnostic workup of challenging spindle cell tumors of the breast as a highly specific marker for metaplastic carcinomas...
  28. doi request reprint Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma
    Adam D Toll
    Department of Pathology, Thomas Jefferson University, Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 19107, USA
    Hum Pathol 41:1205-9. 2010
    ..Our study suggests that E-cadherin down-regulation may lead to enhancer of zeste homologue 2-mediated invasion and metastasis...
  29. ncbi request reprint The reversible epigenetic silencing of BRM: implications for clinical targeted therapy
    S Glaros
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI, USA
    Oncogene 26:7058-66. 2007
    ..Thus, BRG1 and BRM are silenced by different mechanisms, and it may be possible to clinically target and reexpress BRM in a number of tumor types, potentially impacting tumor development...
  30. ncbi request reprint The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer
    Michael Zeidler
    Department of Pathology and Comprehensive Cancer Center, University of Michigan, 3510C MSRB1, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    J Mol Histol 37:219-23. 2006
    ..In this review we summarize the current knowledge on the function of EZH2 in cancer, with special focus on breast cancer, and propose a link between EZH2, the homologous recombination pathway of DNA repair, and breast tumorigenesis...
  31. ncbi request reprint Significance of flat epithelial atypia on mammotome core needle biopsy: Should it be excised?
    Lakshmi P Kunju
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI 48331, USA
    Hum Pathol 38:35-41. 2007
    ..Chronic inflammation and stromal changes are present in a subset of cases. Flat epithelial atypia shows a risk of upgrade to carcinoma similar to that of ADH and, hence, should be recognized and warrants a follow-up excision...
  32. ncbi request reprint WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Celina G Kleer
    Department of Pathology, Univeristy of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res 6:R110-5. 2004
    ..We have demonstrated that WISP3 has tumor growth and angiogenesis inhibitory functions in IBC. We proposed that RhoC and WISP3 cooperate in the development of IBC...
  33. ncbi request reprint Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis
    Agnieszka K Witkiewicz
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 14:1418-23. 2005
    ..Quantitative image analysis is a novel way to accurately and reproducibly evaluate immunohistochemistry in breast tissue samples using high-density tissue microarrays...
  34. ncbi request reprint Small (< 2.0-cm) breast cancers: mammographic and US findings at US-guided cryoablation--initial experience
    Marilyn A Roubidoux
    Department of Radiology, University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Drive, Room 2910H, Ann Arbor, MI 48109 0326, USA
    Radiology 233:857-67. 2004
    ..To determine the mammographic and ultrasonographic (US) findings at cryoablation of small solitary invasive breast cancers and compare them with presence of residual malignancy after treatment...
  35. ncbi request reprint Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy
    Amina Khan
    Department of Surgery, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, USA
    Ann Surg Oncol 12:697-704. 2005
    ..We report the accuracy of comprehensive pre-neoadjuvant CTX and post-neoadjuvant CTX axillary staging via ultrasound imaging, fine-needle aspiration (FNA) biopsy, and SLN biopsy...
  36. ncbi request reprint Expression of polycomb group protein EZH2 in nevi and melanoma
    Jonathan B McHugh
    Department of Pathology, University of Michigan, 1301 Catherine Road, Ann Arbor, MI 48109, USA
    J Cutan Pathol 34:597-600. 2007
    ..We sought to determine the pattern of EZH2 expression in benign and malignant melanocytic tumors to see if EZH2 might play a role in melanoma pathogenesis and progression...
  37. ncbi request reprint Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues
    Lei Ding
    Department of Pathology, University of Michigan Medical School, Ann Arbor 48109, USA
    Cancer Res 66:4095-9. 2006
    ..We identify EZH2 as a potential marker for detecting preneoplastic lesions of the breast in vivo and as a possible target for preventative intervention...
  38. pmc Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients
    An Chi Lo
    Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    Breast 18:55-9. 2009
    ..Future studies should focus on relating epidemiologic factors to molecular features of IBC in this population...
  39. pmc Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks
    Suling Liu
    Comprehensive Cancer Center and School of Dentistry, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 71:614-24. 2011
    ..Bone marrow-derived MSCs may accelerate human breast tumor growth by generating cytokine networks that regulate the CSC population...
  40. pmc Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients
    An Chi Lo
    Department of Epidemiology, University of Michigan School of Public Health, 109 Observatory Street, Ann Arbor, MI 48109, USA
    Breast Cancer Res Treat 112:141-7. 2008
    ..A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors...
  41. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  42. ncbi request reprint Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy
    Anne F Schott
    Hematology Oncology Division, Department of Internal Medicine, University of Michigan, MI 48109 0848, USA
    Breast Cancer Res Treat 92:231-8. 2005
    ....
  43. ncbi request reprint Lymphocytic mastitis and diabetic mastopathy: a molecular, immunophenotypic, and clinicopathologic evaluation of 11 cases
    Riccardo Valdez
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Mod Pathol 16:223-8. 2003
    ..These findings suggest that despite the presence of B-cell-predominant lymphoid infiltrates and lymphoepithelial lesions, lymphocytic mastitis and diabetic mastopathy do not appear to be associated with an increased risk for lymphoma...
  44. ncbi request reprint Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy
    Quintin Pan
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Cancer Res 65:8366-71. 2005
    ..Taken together, these results revealed that PKC epsilon plays a critical and causative role in promoting an aggressive metastatic breast cancer phenotype and as a target for anticancer therapy...
  45. ncbi request reprint Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis
    Robert T Pu
    Department of Pathology, University of Michigan, Ann Arbor, MI, USA
    Am J Surg Pathol 29:354-8. 2005
    ..0062, P = 0.0249, and P = 0.0021, respectively). Although preliminary, our study suggests that the presence of tumor necrosis and ALI in the core biopsy may be important features to be included in the standard report...
  46. ncbi request reprint Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells
    Dinesh S Rao
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor 48109, USA
    Cancer Cell 3:471-82. 2003
    ..Thus, HIP1 overexpression promotes tumor formation and is associated with a general alteration in receptor trafficking. HIP1 is the first endocytic protein to be directly implicated in tumor formation...
  47. pmc Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells
    Wei Huang
    Department of Pathology, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 70:3340-50. 2010
    ..These results enable us to pinpoint one mechanism by which CCN6 controls survival of breast cells mediated by the PI3K/Akt-1 pathway...
  48. ncbi request reprint Sentinel node biopsy prior to neoadjuvant chemotherapy
    Michael S Sabel
    Breast Oncology Program and Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Am J Surg 186:102-5. 2003
    ..Sentinel lymph node biopsy prior to induction chemotherapy may address both...
  49. doi request reprint Residual disease after re-excision lumpectomy for close margins
    Michael S Sabel
    Division of Surgical Oncology, Department of Surgery, Biostatistics Core of the University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Surg Oncol 99:99-103. 2009
    ..We sought to examine the incidence of residual disease after re-excision for close margins and to identify predictive factors that may better select patients for re-excision...
  50. pmc AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist
    Daniel R Rhodes
    Michigan Center for Translational Pathology, Howard Hughes Medical Institute, and Departments of Urology, and Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 5602
    Proc Natl Acad Sci U S A 106:10284-9. 2009
    ..Taken together, these observations indicate that marked AGTR1 overexpression defines a subpopulation of ER-positive, ERBB2-negative breast cancer that may benefit from targeted therapy with AGTR1 antagonists, such as losartan...
  51. pmc BRCA1 regulates human mammary stem/progenitor cell fate
    Suling Liu
    Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 105:1680-5. 2008
    ..Because BRCA1 also plays a role in DNA repair, our work suggests that loss of BRCA1 may result in the accumulation of genetically unstable breast stem cells, providing prime targets for further carcinogenic events...
  52. ncbi request reprint Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines
    Michael E Ray
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0948, USA
    Cancer Res 64:40-7. 2004
    ..This study has identified new candidate oncogenes within the 8p11-p12 region, supporting the hypothesis that genes other than FGFR1 may contribute to oncogenesis in breast cancers with proximal 8p amplification...
  53. ncbi request reprint Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis
    Merav A Ben-David
    Department of Radiation Oncology, Cancer and Geriatrics Center, University of Michigan Medical School, Ann Arbor, Michigan 48109 0010, USA
    Cancer 106:28-34. 2006
    ....
  54. pmc ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease
    Rainer Kuefer
    Department of Urology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109 0944, USA
    Neoplasia 8:319-29. 2006
    ..These results suggest that ADAM15 is generally overexpressed in adenocarcinoma and is highly associated with metastatic progression of prostate and breast cancers...
  55. ncbi request reprint Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis
    Quintin Pan
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 62:4854-9. 2002
    ..Our study suggests that a major mechanism of the antiangiogenic effect of copper deficiency induced by TM is suppression of NFkappaB, contributing to a global inhibition of NFkappaB-mediated transcription of proangiogenic factors...
  56. ncbi request reprint Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma
    Quintin Pan
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Mol Cancer Ther 2:617-22. 2003
    ..4 +/- 14.3% greater than that in doxorubicin-treated mice. These results suggest that TM may enhance the rate of pathological complete response when used in combination with an anthracycline in neoadjuvant therapy of breast carcinoma...
  57. pmc Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia
    Xin Li
    Department of Pathology, University of Michigan Medical School, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Am J Pathol 175:1246-54. 2009
    ....
  58. pmc Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast
    Michael J Hayes
    Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Clin Cancer Res 14:4038-44. 2008
    ..Given the role of the Wnt pathway in cell fate and in the development of breast cancer, we hypothesized that defects in this pathway may contribute to the development of metaplastic carcinomas...
  59. pmc Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression
    Celina G Kleer
    Department of Pathology, University of Michigan Cancer Center, Ann Arbor, Michigan, USA
    Clin Cancer Res 14:5357-67. 2008
    ..To evaluate the expression of cathepsin K (CTSK) and CXCL14 in stromal and epithelial cells in human breast tumor progression...
  60. ncbi request reprint Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board
    Erika A Newman
    Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Cancer 107:2346-51. 2006
    ..The purpose of the current study was to evaluate the impact of this approach on the surgical management of breast cancer...
  61. ncbi request reprint Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions
    Ming Zhou
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, USA
    Am J Surg Pathol 26:926-31. 2002
    ..In conclusion, our study suggests that AMACR is potentially an important tumor marker for several cancers and their precursor lesions, especially those linked to high-fat diets...
  62. pmc African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study
    Azadeh Stark
    Department of Pathology, Ford Health System, Detroit, Michigan, USA
    Cancer 116:4926-32. 2010
    ..The study of breast cancer in women with African ancestry offers the promise of identifying markers for risk assessment and treatment of triple-negative disease...
  63. pmc CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature
    Zhenhua Miao
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    Proc Natl Acad Sci U S A 104:15735-40. 2007
    ..Taken together, these data suggest that CXCR7 has key functions in promoting tumor development and progression...
  64. ncbi request reprint Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast
    Frances P O'Malley
    Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Mod Pathol 19:172-9. 2006
    ..1-97.4%), than for determining its presence (90.4%: 95% CI, 79.9-96.7%). We conclude that the diagnosis of FEA and its distinction from CCLs without atypia is highly reproducible with the use of available diagnostic criteria...
  65. ncbi request reprint A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity
    Vered Stearns
    Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Clin Cancer Res 10:8332-40. 2004
    ..We chose tamoxifen to establish proof of principal with a known effective agent...
  66. ncbi request reprint Sentinel lymph node biopsy for breast cancer: how many nodes are enough?
    Shaheen Zakaria
    Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA
    J Surg Oncol 96:554-9. 2007
    ..Sentinel lymph node (SLN) biopsy using blue dye and radioisotope often results in the removal of multiple SLNs. We sought to determine whether there is a point where the surgeon can terminate the procedure without sacrificing accuracy...
  67. ncbi request reprint Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells
    Julie Hanson Ostrander
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Cancer Res 67:4199-209. 2007
    ..These results place Brk in a novel signaling pathway downstream of ErbB receptors and upstream of Rac, p38 MAPK, and ERK5 and establish the ErbB-Brk-Rac-p38 MAPK pathway as a critical mediator of breast cancer cell migration...
  68. ncbi request reprint A putative role for psoriasin in breast tumor progression
    Ian Krop
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:11326-34. 2005
    ....

Research Grants9

  1. Role of LIBC in Inflammatory Breast Cancer Phenotype
    Celina Kleer; Fiscal Year: 2007
    ..Also, understanding the role of WISP3 will shed light on the mechanisms of cancer development in general and serve as a model for other related CCN genes involved in carcinogenesis. ..
  2. Role of EZH2 in Breast Cancer
    Celina Kleer; Fiscal Year: 2006
    ..In summary, this proposal addresses the clinical utility and functional role of EZH2 in the regulation of breast cancer progression. ..
  3. Role of EZH2 in Breast Cancer
    Celina Kleer; Fiscal Year: 2009
    ..In summary, this proposal addresses the clinical utility and functional role of EZH2 in the regulation of breast cancer progression. ..
  4. Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
    Celina Kleer; Fiscal Year: 2009
    ..These studies may form the basis of intervention and therapy in breast cancer, potentially preventing premalignant lesions from becoming malignant and metastasizing. ..
  5. Role of EZH2 in Breast Cancer
    Celina Kleer; Fiscal Year: 2007
    ..In summary, this proposal addresses the clinical utility and functional role of EZH2 in the regulation of breast cancer progression. ..
  6. Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
    Celina G Kleer; Fiscal Year: 2010
    ..These studies may form the basis of intervention and therapy in breast cancer, potentially preventing premalignant lesions from becoming malignant and metastasizing. ..
  7. Role of EZH2 in Breast Cancer Progression
    Celina G Kleer; Fiscal Year: 2010
    ..These studies may form the basis of intervention and therapy in breast cancer, potentially preventing premalignant lesions from becoming malignant and metastasizing. ..